Alterity Therapeutics Limited American Depositary Shares (ATHE) is a publicly traded Healthcare sector company. As of May 19, 2026, ATHE trades at $4.13 with a market cap of $73.05M and a P/E ratio of 0.00. ATHE moved +0.00% today. Year to date, ATHE is +37.18%; over the trailing twelve months it is +5.73%. Its 52-week range spans $1.00 to $7.00. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces ATHE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alterity Targets Mid-2026 FDA Meeting After ATH434 Shows 48% UMSARS-I Slowing: Alterity Therapeutics will hold an End-of-Phase 2 FDA meeting in mid-2026 to confirm a Phase 3 trial design for ATH434 in multiple system atrophy. Its Phase 2 data showed a 48% slowing of UMSARS-I decline at 50 mg BID (p=0.035) and significant swallowing improvement (p=0.003).
| Metric | Value |
|---|---|
| Price | $4.13 |
| Market Cap | $73.05M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.00 |
| 52-Week Low | $1.00 |
| Volume | 2.61K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover ATHE: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.